Boston Scientific’s Watchman heart implant shows improved safety profile in preliminary results

Boston Scientific's Watchman device illustration

Boston Scientific (NYSE:BSX) today unveiled new results from a clinical trial of its Watchman stroke prevention device, reporting that the cardiac implant met 2 of 3 co-primary endpoints for safety and effectiveness compared with drug therapy.

The company’s PREVAIL trial achieved its 2 safety endpoints, but researchers found no differences in rates of stroke, systemic embolism and cardiovascular or unexplained death at 18 months between patients who received the Watchman device and those who were treated with warfarin, a blood thinner.

The device had success in more success in demonstrating lowered rates of acute death or serious vascular complications related to the procedure in the 7 days following implantation, as well as low rates of ischemic stroke or systemic embolism more than 7 days and up to 18 months following implantation, Boston Scientific announced.

The results were unveiled in a late-breaking trial presentation at the American College of Cardiology conference in San Francisco.

The Watchman device, which is already available in 30 countries, is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there. The device aims to reduce the risk of stroke and may potentially eliminate the need for long-term use of blood-thinning medications.

Boston Scientific was pressured into releasing its PREVAIL full study results this weekend, after conference organizers and Wall Street analysts balked at the company’s announcement that it would unveil only the acute procedural safety results from the trial.

The exclusion made headlines, and Boston Scientific reported shortly after that it would scramble to ensure that results for all 3 co-primary endpoints were ready for presentation.

The failure to meet comparative effectiveness endpoints may bode ill for the Watchman device as it aims for FDA approval, but the researchers appeared confident with the new results.

"I believe this information will reassure the FDA and the cardiovascular community about the improved safety and efficacy of this procedure and device, which has been implanted in more than 2,000 patients world-wide," co-principal investigator and Mayo Clinic professor Dr. David Holmes said in prepared remarks. "This is an important part of the journey to develop new strategies for stroke prevention in atrial fibrillation to avoid the need for long-term or life-long anticoagulation in some patients. Such a device can make a tremendous difference for patients with atrial fibrillation."

The PREVAIL trial was launched in order to address safety concerns raised by a previous Watchman trial, Boston Scientific noted. The PROTECT AF trial showed that treatment with the Watchman device reduced a patient’s risk of hemorrhagic stroke compared with warfarin, but also showed an increase in procedure-related adverse events.

Natick, Mass.-based Boston Scientific acquired the Watchman device along with AtriTech for up to $375 million in 2011. Last summer the company closed enrollment in a 2nd trial of the device, with more than 2,000 subjects signing on for the randomized comparison of Watchman with warfarin in high-risk patients with atrial fibrillation. In August the device won expanded CE Mark approval in the European Union for the catheter-based clot-capture system, to patients with atrial fibrillation who can’t be treated with warfarin or new oral anticoagulants.

RSS From Medical Design & Outsourcing

  • Herrmann Ultrasonics, Inc. announces its 25 Year Anniversary
    In 1990, Thomas Herrmann, the son of Walter Herrmann, who founded Herrmann Ultraschalltechnik GmbH in 1961, established Herrmann Ultrasonics Inc. in the Chicago area. Hermann Ultrasonics, Inc. is proud to recognize a milestone year in observance of their 25th anniversary. Herrmann Ultrasonics has been focused on providing ultrasonic welding technology for various markets such as […]
  • Consumer Health Applications receive the most attention today, but the future is elsewhere
    Wearables for health fall into a wide range of technologies, functions, use cases and over-arching regulatory frameworks that developers and prospective entrants have to understand in order to effectively compete. Using an underlying taxonomy for human health, we establish a health-focused wearables taxonomy around three major categories—applications, use cases, and form factors—the three areas critical […]
  • Paralyzed men move legs with new non-invasive spinal cord stimulation
    Five men with complete motor paralysis were able to voluntarily generate step-like movements thanks to a new strategy that non-invasively delivers electrical stimulation to their spinal cords, according to a new study funded in part by the National Institutes of Health. The strategy, called transcutaneous stimulation, delivers electrical current to the spinal cord by way […]
  • SCHURTER’s new power entry module offers IP 54 protection with V-Lock cord sets
    SCHURTER is pleased to announce, that its power entry module, series 5707, now offers IP 54 protection with V-Lock cord sets at the power input, in addition to IP 65 protection to the equipment. The sealed module is ideal for use in medical equipment exposed to leaks, drips and spills, as well as equipment subject […]
  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]

Leave a Reply